XML 62 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Current assets:      
Cash and cash equivalents $ 7,935 $ 5,530  
Short-term investments 10,734 5,708  
Prepaid clinical trial expenses 748 71  
Other prepaid expenses and current assets 248 296  
Total current assets 19,665 11,605  
Property and equipment, net 119 167  
Other assets 10 413  
Total assets 19,794 12,185  
Current liabilities:      
Accounts payable 1,998 1,419  
Accrued clinical trial costs 820 1,141  
Accrued expenses 866 1,468  
Total current liabilities 3,684 4,028  
Long-term liabilities      
Warrant liability 1,700 0  
Total liabilities 5,384 4,028  
Commitments and contingencies (Note 9)  
Stockholders' equity      
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively 0 0  
Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2024 and December 31, 2023; 13,481,917 and 5,754,505 issued and outstanding at December 31, 2024 and December 31, 2023, respectively 4 1  
Additional paid-in capital 174,166 154,218  
Accumulated deficit (159,764) (146,064)  
Accumulated other comprehensive income 4 2  
Total stockholders' equity 14,410 8,157 $ (71,304)
Total liabilities and stockholders' equity $ 19,794 $ 12,185